Search
Please see below for a list of search results.
EU Directives are being put in place for the coding and import of tissues and cells for human application (HA). These will be transposed into UK law during 2016 and the process of writing the UK Regulations is underway.Copies of these Directives and an overview from the Department of Health (DH...
The Human Tissue Authority (HTA) welcomes the publication of the report from the Regenerative Medicine Expert Group, “Building on our own potential: a UK pathway for regenerative medicine”.
HTA-licensed establishments in the post mortem sector are required to report incidents (HTARIs), and those in the human application and organ donation and transplantation sectors are required to report serious adverse events or reactions (SAEARs), as part of their licensing with us.
This policy has been developed by the HTA in order to provide clarification and to assure consistency in the way licensed establishments apply the mandatory testing requirements for HTLV-1 testing.
The HTA was asked to share a letter written to the University of Bristol regarding a process taking place at the university in 2008, as part of a process to create an artificial trachea for transplant
Issued 2 November 2016
Notice for
• Designated Individuals (DIs) in the Human Application (HA) sector • Licence contacts in the Organ Donation and Transplantation (ODT) sector
Issued 10 May 2017
Notice for
• Designated Individuals (DIs) in the Human Application (HA) sector
Scope
The European Commission is consulting on the EU legislation on blood, tissues and cells.
Are you considering banking your baby’s umbilical cord blood? Have you come across our cord blood-banking guide before?
New EU regulations for medical devices (MDR) and in-vitro medical devices (IVDR) have been introduced. These regulations entered into force on 25 May 2017 across EU Member States. However, most requirements will not fully apply until 26 May 2020 for the MDR, and 26 May 2022 for the IVDR.